

COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

RECENT NEWS

Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones

Mar 17 2021, 8:30 AM EDT

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

Mar 10 2021, 8:00 AM EST

Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

Mar 9 2021, 7:00 AM EST

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

INVESTOR RELATIONS

LHA Investor Relations
Jody Cain
T: 310-691-7100
jcain@lhai.com

MANAGEMENT TEAM

Gary Wilcox, Ph.D.

Chairman of the Board and Chief Executive Officer

Sam Lee, Ph.D.

President

James J. Martin

Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.